Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Casdozokitug · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Arm A: Casdozokitug Lower Dose + Toripalimab + Bevacizumab | EXPERIMENTAL | - |
| Arm B: Casdozokitug Higher dose + Toripalimab + Bevacizumab | EXPERIMENTAL | - |
| Arm C: Toripalimab + Bevacizumab | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| Casdozokitug | DRUG | Solution for infusion |
| Toripalimab | DRUG | Solution for infusion |
| Bevacizumab | DRUG | Solution for infusion |
Key Inclusion Criteria: * Unresectable locally advanced or metastatic HCC with diagnosis confirmed by histology/cytology or clinically by American Association for the Study of Liver Diseases criteria in cirrhotic participants. * Disease that is not amenable to curative surgical and/or locoregional ...
Casdozokitug is an investigational small molecule being developed for the treatment of hepatocellular carcinoma, specifically in patients with unresectable and/or locally advanced or metastatic disease. It is currently being studied in a Phase 2 clinical trial in combination with toripalimab plus bevacizumab.
Casdozokitug is being developed by Coherus Oncology, Inc., a subsidiary of Coherus BioSciences, Inc. (NASDAQ: CHRS). The company is conducting a Phase 2 clinical trial to evaluate the drug in combination with toripalimab and bevacizumab for hepatocellular carcinoma.
Casdozokitug is currently in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The ongoing Phase 2 trial is active but not recruiting participants, with a planned enrollment of 72 patients.
Casdozokitug is being evaluated in a Phase 2 trial with the identifier NCT06679985. This trial is studying the drug in combination with toripalimab plus bevacizumab in participants with unresectable and/or locally advanced or metastatic hepatocellular carcinoma. The trial is active but not recruiting, with an enrollment of 72 participants.
Yes, Casdozokitug is a small molecule therapeutic. It is being developed as an oncology treatment for hepatocellular carcinoma. The drug is currently in Phase 2 clinical trials, and its mechanism of action has not been disclosed in available information.